Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.58 |
| ▸ | NPY1R | P25929 | 8/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.58 |
| ▸ | NPY2R | P49146 | 4/20 | 0.58 |
| ▸ | TFPI | P10646 | 1/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29835241 | 0.97 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29835305 | 0.95 | TFPI (0.61) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL30924746 | 0.95 | TFPI (0.59) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL30924750 | 0.94 | TFPI (0.60) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL30924753 | 0.92 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL30924727 | 0.91 | TFPI (0.54) | NPY4RNPY1RNPY2RTFPIKISS1R | |
| SCHEMBL30612278 | 0.90 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29434670 | 0.90 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30924735 | 0.90 | TFPI (0.59) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29835247 | 0.88 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026787-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | GLO PHARMA, INC. | 2025-01-23 | — | — | US | disclosed |
| US-12162956-B2 | Peptides and methods for reducing skin pigmentation | GLO PHARMA, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240190917-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | GLO PHARMA, INC. | 2024-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190917-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | MC1R, TYR, MC5R | NPY4R 66/4885NPY1R 29/4885NPY5R 38/4885 |
| US-12162956-B2 | Peptides and methods for reducing skin pigmentation | MC1R, TYR, MC5R | NPY4R 66/4885NPY1R 29/4885NPY5R 38/4885 |
| US-20250026787-A1 | PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION | MC1R, TYR, MC5R | NPY4R 66/4885NPY1R 29/4885NPY5R 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.